Wharton Business Group’s Emergent Biosolutions EBS Stock Holding History

Wharton Business Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,927	Closed	-$275K	–	102
2017 Q4	$275K	Sell	5,927 -6,000	-50%	-$253K	0.03%	91
2017 Q3	$482K	Hold	11,927	–	–	0.05%	75
2017 Q2	$404K	Hold	11,927	–	–	0.04%	87
2017 Q1	$346K	Hold	11,927	–	–	0.04%	91
2016 Q4	$392K	Hold	11,927	–	–	0.05%	89
2016 Q3	$376K	Hold	11,927	–	–	0.05%	96
2016 Q2	$335K	Hold	11,927	–	–	0.04%	105
2016 Q1	$434K	Hold	11,927	–	–	0.05%	100
2015 Q4	$477K	Hold	11,927	–	–	0.05%	100
2015 Q3	$340K	Hold	11,927	–	–	0.03%	107
2015 Q2	$393K	Hold	11,927	–	–	0.03%	110
2015 Q1	$343K	Sell	11,927 -27,500	-70%	-$789K	0.03%	116
2014 Q4	$1.07M	Sell	39,427 -7,500	-16%	-$179K	0.09%	95
2014 Q3	$1M	Buy	+46,927	New	+$1.07M	0.09%	101

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wharton Business Group's EBS Position: Q1 2018 in Review

Wharton Business Group sold out of Emergent Biosolutions (EBS) in Q1 2018, closing a stake of 5,927 shares — an estimated $275K sold.

Wharton Business Group first reported a position in EBS in Q3 2014 and held it in 14 quarters. The position peaked at $1.07M in Q4 2014. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2018.

Wharton Business Group reported no remaining Emergent Biosolutions position as of Q1 2018 after selling out during the quarter.
Wharton Business Group sold 5,927 Emergent Biosolutions shares in Q1 2018, an estimated $275K.
Wharton Business Group first reported a position in Emergent Biosolutions in Q3 2014 and held it in 14 quarters.
Wharton Business Group's Emergent Biosolutions position peaked at $1.07M in Q4 2014.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2018.

Based on Wharton Business Group's 13F filing for Q1 2018, filed 3 May 2018.